FR2710267A1 - Composition for the treatment of male impotence - Google Patents

Abstract

Composition for the treatment of male impotence, comprising, as percentages of the total weight of the composition, 6 to 11.5% of ursodeoxycholic acid, 20 to 40% of Panax ginseng extract, 2.5 to 6% of Muira puama extract, 0.7 to 1.5% of yohimbine hydrochloride, 3 to 6.5% of guarana extract, 0.2 to 0.6% of nux vomica extract, 6.5 to 12% of damiana extract, 8 to 14% of nicotinamide, 6 to 11.5% of nicotinic acid, 3 to 6.5% of L-tocopherol acetate, 0.003 to 0.01% of clenbuterol hydrochloride and 12 to 20% of an excipient.

Description

COMPOSITION FOR THE TREATMENT OF MALE IMPOTENCE

  The present invention relates to a composition for the treatment of male impotence. In its simplest definition, male impotence is the impossibility of obtaining an erection, a

ejaculation or both.

  The penile erection is initiated by neuropsychological stimuli causing vasodilation of the areolar spaces and arteries at

breast of the two cavernous bodies.

  From the central nervous system, the seat of these stimuli, the nerve impulse is transmitted to the vascular system via the peripheral nervous system, i.e. the sympathetic system

and parasympathetic.

  Three anatomical systems are therefore involved in the mechanisms of erection: the central nervous system, the peripheral nervous system and the system

vascular.

  Impotence is schematically classified into 2 etiological groups: - impotence of organic origin linked to a primary or secondary attack of the central nervous system, the peripheral nervous system or the vascular system,

  - impotence of psychogenic origin.

  The treatments proposed for male impotence in the Prior Art are numerous: - mechanical treatments such as vacuum devices, elastic ribbons, ...; - drug treatments mainly represented by the use of vasoactive substances: yohimbine by general route and especially papaverine by local route (injection into the corpora cavernosa); - surgical treatments consisting essentially of the fitting of penile prostheses,

  reserved for patients refractory to other therapies and whose esthetic and functional performances are not always satisfactory.

  In view of the imperfections and risks presented by these various treatments, the inventor set himself the aim of providing a composition which can be administered orally and which is capable of effectively treating male impotence and, in particular to facilitate erection, being devoid of effects

unwanted side effects.

  The present invention therefore relates to a composition for the treatment of male impotence, characterized in that it has the following formulation, expressed as percentages of the total weight of the composition: - ursodeoxycholic acid ...... .......

  ..... 6 to 11.5% - Panax ginseng extract ..................... 20 to 40% extract of Muira puama ..... .................. 2.5 to 6% - yohimbine hydrochloride .................. 0.7 to 1.5% - Guarana extract ........................... 3 to 6.5% - vomit nut extract .... DTD: ............... 0.2 to 0.6% - extract from Damiana .................... ..... DTD:. 6.5 to 12% nicotinamide .................................. 8 to 14% - nicotinic acid .. ......................... 6 to 11.5% - L-tocopherol acetate ............. ......... 3 to 6.5% - clenbuterol hydrochloride ............. 0.003 to 0.01% - suitable excipient ......... .... DTD: ............ 12 to 20% In a preferred embodiment of the invention, the composition has the following formulation expressed in percentages of the total weight of the composition: - ursodeoxycholic acid ......................... 8.8% - Panax ginseng extract .............. ............ 30% - extract from Muira puama .......................... 4.32% - yohimbine hydrochloride ... DTD: .................... 1.12% - Guarana extract .............. ........... DTD: ...... 4.8% - vomit nut extract ...................... .... 0.6% - Damiana extract ............................... 9.2% nicotinamide .. .................................. 11.2% - nicotinic acid ......... ........................ 22% - Ltocopherol acetate .......................... 4.8% - Clenbuterol hydrochloride ... DTD: ....... ......... 0.0048% - suitable excipient ......................... DTD:. Advantageously, the suitable excipient is chosen from lactose, silica, talc, starch ,..DTD: magnesium stearate or their mixtures.

  In a particularly advantageous manner, the composition can be administered orally in the form

  250 mg tablets or capsules.

  Indeed, the Inventor has discovered that by combining: - the peripheral vasodilator properties of yohimbine hydrochloride, an alkaloid extracted from Corynanthe yohimbe, - the stimulating properties on the nervous system

  central and peripheral nervous system and anti

  asthenic that have the extracts, on the one hand, of the root of Panax ginseng and, on the other hand, of Paullinia cupana also called Guarana, the stimulating effects on muscle tone (increased reflex excitability) exerted by the two alkaloids contained in the extract of the vomit nut, namely strychnine and lorucine, the stimulating action exerted on the central nervous system by the extract of Muira puama, as well as the stimulating action exerted on the peripheral nervous system, in particular, the parasympathetic system sacred by the extract of Damiana or Turnera aphrodisiac,

  - the vasodilating action exerted by clenbuterol, -

  stimulating, on the coronaries and on the striated muscles as well as the P-mimetic action of this compound capable of stimulating ejaculation, - the vasodilatory properties of nicotinamide as well as nicotinic acid, - the stimulating properties of acetate L-tocopherol or vitamin E on the development of sex cells, - the protective action exerted by ursodeoxycholic acid on the liver and bile ducts and, provided these different compounds are brought together in appropriate proportions, a synergy of these properties being reflected in the subjects treated by a significant reduction in male impotence disorders. 15 EXAMPLE OF THE PRODUCTION OF A COMPOSITION CONFORMING TO

THE INVENTION:

  A composition in accordance with the invention is prepared by mixing the various constituents so as to obtain, per tablet or capsule of 250 mg: 20 - ursodeoxycholic acid ......... 22 mg (or 8.8%) - Panax ginseng extract ......... 75 mg (i.e. 30%) - Muira puama extract ......... 10.8 mg (i.e. 4.32%) - yohimbine hydrochloride. ...... 2.8 mg (i.e. 1.12%) - Guarana extract ............... 12 mg (i.e. 4.8%) - vomit nut extract ......... 1.5 mg (or 0.6%) - Damiana extract ............... 23 mg (or 9.2%) - nicotinamide .............

  ...... 28 mg (i.e. 11.2%) - nicotinic acid ................ 22 mg (i.e. 22%) - L-tocopherol acetate ... ....... 12 mg (i.e. 4.8%) - clenbuterol hydrochloride ... 0.012 mg (i.e. 0.0048%) - suitable excipient .......... 40.88 mg ( or 16.355%) As appears from the above, the invention is in no way limited to the embodiment which has just been described in a more explicit manner; on the contrary, it embraces all the variants which can come to the mind of the technician in the matter, without departing from the framework or the scope of the present invention ... DTD:

Claims (4)

  1. Composition for the treatment of male impotence, characterized in that it has the following formulation, expressed in percentages of the total weight of the composition: - ursodeoxycholic acid .............. ...... 6 to 11.5% - Panax ginseng extract ..................... 20 to 40% - Muira puama extract ... .................... 2.5 to 6% - yohimbine hydrochloride .................. 0.7 to 1.5% - Guarana extract .........   ................ 3 to 6.5% - vomit nut extract .................. CLMF: .. 0 , 2 to 0.6% - Damiana extract .......................... 6, 5 to 12% - nicotinamide ..... ............................. 8 to 14% - nicotinic acid .............. ............. 6 to 11.5% - L-tocopherol acetate ...................... 3 to 6 , 5% - clenbuterol hydrochloride ............. 0.003 to 0.01% - suitable excipient ........... CLMF: ........ ...... 12 to 20% .. CLMF: 2. Composition according to Claim 1,   characterized in that it has the following formulation expressed as a percentage of the total weight of the composition: - ursodeoxycholic acid ......................... 8, 8% - Panax ginseng extract .......................... 30% - Muira puama extract .......   ................. 4.32% - yohimbine hydrochloride ................ CLMF: ....... 1.12% - Guarana extract ............................... 4.8% extract of Vomic nut ... ....................... 0.6% - Damiana extract ................... ............ 9.2% - nicotinamide ... CLMF: ........................... ...... 11.2% - nicotinic acid ............ CLMF: ..................... 22% - L-tocopherol acetate .................. CLMF: ........ 4.8% - clenbuterol hydrochloride ........ ........... 0.0048% - suitable excipient .......................... 16.355% 3. Composition according to Claim 1 or Claim 2, characterized in that the suitable excipient is chosen from lactose, silica, talc, starch, magnesium stearate or their mixtures. 4. Composition according to any one of..CLMF: Previous claims, characterized in that it   can be administered orally in tablet form or 250 mg capsules.